Profile data is unavailable for this security.
About the company
DexCom, Inc. is a medical device company. The Company is primarily focused on the design, development, and commercialization of continuous glucose monitoring (CGM), systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. Its products include Dexcom G6, Dexcom G7, Stelo, Dexcom Share, and Dexcom ONE. The Company enables people to take control of health through innovative biosensing technology. Dexcom G6 is its integrated continuous glucose monitoring system (iCGM). Stelo is designed specifically for people with type II diabetes who do not use insulin as the first over-the-counter glucose biosensor in the United States. The Dexcom Share remote monitoring system, offered for use with any Dexcom system, uses an app on the patient’s compatible mobile device. Its Dexcom G7 is for adults and children (2+ years) living with type I or type II diabetes who are on any insulin or medications, at risk of hypoglycemia, and those with gestational diabetes.
- Revenue in USD (TTM)4.66bn
- Net income in USD836.30m
- Incorporated1999
- Employees11.00k
- LocationDexcom Inc6340 Sequence DriveSAN DIEGO 92121United StatesUSA
- Phone+1 (302) 636-5400
- Fax+1 (302) 636-5454
- Websitehttps://www.dexcom.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cooper Companies Inc | 4.09bn | 374.90m | 16.37bn | 15.00k | 44.79 | 2.00 | 21.77 | 4.00 | 1.87 | 1.87 | 20.46 | 42.06 | 0.3312 | 1.71 | 5.29 | 272,826.70 | 3.03 | 8.04 | 3.32 | 8.86 | 65.54 | 66.01 | 9.16 | 24.66 | 1.13 | 6.32 | 0.2332 | 0.2049 | 5.06 | 10.98 | -4.44 | 9.48 | 3.15 | -- |
| Hologic Inc | 4.13bn | 543.80m | 16.84bn | 7.07k | 31.31 | 3.21 | 20.07 | 4.08 | 2.41 | 2.41 | 18.28 | 23.51 | 0.4608 | 2.57 | 6.79 | 583,663.40 | 6.07 | 11.22 | 6.82 | 12.85 | 56.51 | 60.20 | 13.18 | 21.99 | 3.32 | 15.76 | 0.3246 | 0.00 | 1.74 | 1.66 | -28.35 | -12.69 | -0.5168 | -- |
| Insulet Corp | 2.71bn | 247.10m | 17.28bn | 5.40k | 70.12 | 11.40 | 51.18 | 6.38 | 3.50 | 3.50 | 37.86 | 21.53 | 0.8628 | 1.74 | 6.14 | 501,518.50 | 7.87 | 7.14 | 9.75 | 8.51 | 71.63 | 68.72 | 9.13 | 10.06 | 2.15 | 46.91 | 0.3852 | 0.00 | 30.73 | 24.53 | -40.93 | 105.15 | 5.67 | -- |
| West Pharmaceutical Services Inc | 3.07bn | 493.70m | 18.10bn | 10.80k | 36.98 | 5.70 | 27.81 | 5.89 | 6.79 | 6.79 | 42.28 | 44.11 | 0.7769 | 4.80 | 5.40 | 284,638.90 | 12.11 | 15.24 | 14.29 | 18.19 | 35.91 | 37.89 | 15.59 | 18.67 | 2.34 | -- | 0.0614 | 10.13 | 6.25 | 7.44 | 0.203 | 7.36 | 10.39 | 5.51 |
| Zimmer Biomet Holdings Inc | 8.23bn | 704.60m | 19.47bn | 17.00k | 28.06 | 1.53 | 10.82 | 2.36 | 3.55 | 3.55 | 41.44 | 64.95 | 0.3703 | 1.10 | 5.17 | 484,211.80 | 3.17 | 3.03 | 3.58 | 3.46 | 69.71 | 71.01 | 8.56 | 9.10 | 1.10 | 4.71 | 0.3718 | 29.26 | 7.20 | 6.08 | -21.98 | -- | 9.26 | 0.00 |
| Illumina Inc | 4.34bn | 850.00m | 20.32bn | 8.60k | 24.26 | 7.47 | 18.14 | 4.68 | 5.48 | 5.48 | 27.88 | 17.80 | 0.6709 | 2.61 | 5.34 | 505,000.00 | 13.13 | -10.15 | 17.32 | -12.15 | 66.61 | 65.39 | 19.57 | -23.18 | 1.72 | 15.79 | 0.4221 | -- | -0.6633 | 6.04 | 169.50 | 5.32 | -4.77 | -- |
| Steris PLC | 5.83bn | 708.66m | 24.30bn | 17.79k | 34.48 | 3.40 | 20.30 | 4.17 | 7.19 | 7.18 | 59.09 | 72.93 | 0.5658 | 4.92 | 6.12 | 327,662.40 | 6.91 | 5.04 | 7.59 | 5.51 | 44.11 | 43.75 | 12.21 | 10.69 | 1.75 | 20.99 | 0.2094 | 37.51 | 6.24 | 12.49 | 10.64 | 8.40 | 11.52 | 8.99 |
| DexCom Inc | 4.66bn | 836.30m | 28.40bn | 11.00k | 35.71 | 10.34 | 26.10 | 6.09 | 2.07 | 2.07 | 11.50 | 7.14 | 0.727 | 3.02 | 4.20 | 423,818.20 | 13.04 | 8.85 | 21.58 | 12.58 | 62.09 | 63.92 | 17.94 | 14.21 | 1.59 | -- | 0.3204 | -- | 15.60 | 19.33 | 45.14 | 8.75 | 12.81 | -- |
| Veeva Systems Inc | 3.08bn | 860.33m | 29.83bn | 7.29k | 35.29 | 4.24 | 33.14 | 9.68 | 5.14 | 5.14 | 18.41 | 42.84 | 0.4234 | -- | 9.15 | 422,472.40 | 11.83 | 11.33 | 13.50 | 14.35 | 75.67 | 72.60 | 27.93 | 23.96 | -- | -- | 0.00 | 0.00 | 16.20 | 19.99 | 35.84 | 18.85 | 36.56 | -- |
| Waters Corp | 3.17bn | 642.63m | 30.14bn | 7.90k | 28.56 | 7.14 | 35.47 | 9.52 | 10.76 | 10.76 | 53.01 | 43.01 | 0.6574 | 2.46 | 4.05 | 400,669.10 | 13.35 | 17.03 | 16.91 | 21.51 | 59.28 | 59.00 | 20.30 | 22.40 | 1.27 | 15.81 | 0.3546 | 0.00 | 6.99 | 6.00 | 0.7518 | 4.26 | -8.14 | -- |
| Agilent Technologies Inc | 7.07bn | 1.29bn | 33.41bn | 18.10k | 26.09 | 4.84 | 21.24 | 4.73 | 4.53 | 4.53 | 24.81 | 24.44 | 0.5714 | 3.26 | 4.96 | 390,331.50 | 10.43 | 11.44 | 12.51 | 13.67 | 52.53 | 53.25 | 18.26 | 18.82 | 1.59 | 19.12 | 0.3268 | 20.76 | 6.73 | 5.41 | 1.09 | 12.63 | 27.88 | 7.10 |
| GE HealthCare Technologies Inc | 20.63bn | 2.09bn | 36.53bn | 54.00k | 17.61 | 3.52 | 13.37 | 1.77 | 4.55 | 4.55 | 45.03 | 22.77 | 0.5893 | 5.93 | 4.31 | 381,944.40 | 6.15 | 6.70 | 8.46 | 9.25 | 39.98 | 40.44 | 10.44 | 10.49 | 1.13 | 9.97 | 0.4866 | 1.85 | 4.84 | 3.74 | 4.57 | 0.7558 | 13.23 | -- |
| Resmed Inc | 5.40bn | 1.49bn | 37.50bn | 10.60k | 25.44 | 5.93 | 22.18 | 6.95 | 10.12 | 10.12 | 36.75 | 43.39 | 0.6901 | 2.34 | 5.53 | 509,256.50 | 19.00 | 15.33 | 21.94 | 17.76 | 60.85 | 57.29 | 27.53 | 21.96 | 2.32 | -- | 0.095 | 28.94 | 9.84 | 11.72 | 37.20 | 17.64 | -1.02 | 1.69 |
Data as of Mar 02 2026. Currency figures normalised to Dexcom Inc's reporting currency: US Dollar USD
37.50%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Dec 2025 | 45.17m | 11.58% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 24.63m | 6.32% |
| SSgA Funds Management, Inc.as of 31 Dec 2025 | 18.09m | 4.64% |
| Baillie Gifford & Co.as of 31 Dec 2025 | 15.55m | 3.99% |
| Geode Capital Management LLCas of 31 Dec 2025 | 11.01m | 2.82% |
| AllianceBernstein LPas of 31 Dec 2025 | 8.62m | 2.21% |
| Norges Bank Investment Managementas of 31 Dec 2025 | 7.28m | 1.87% |
| Jennison Associates LLCas of 31 Dec 2025 | 5.79m | 1.49% |
| Invesco Capital Management LLCas of 31 Dec 2025 | 5.20m | 1.33% |
| JPMorgan Investment Management, Inc.as of 31 Dec 2025 | 4.89m | 1.25% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
